GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Gastric Cancer, Springer Science and Business Media LLC, Vol. 26, No. 1 ( 2023-01), p. 55-68
    Type of Medium: Online Resource
    ISSN: 1436-3291 , 1436-3305
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2023
    detail.hit.zdb_id: 1481763-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Clinical & Experimental Metastasis, Springer Science and Business Media LLC, Vol. 39, No. 2 ( 2022-04), p. 323-333
    Type of Medium: Online Resource
    ISSN: 0262-0898 , 1573-7276
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2022
    detail.hit.zdb_id: 1496876-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 79, No. 13_Supplement ( 2019-07-01), p. 1508-1508
    Abstract: Targeting the dynamic tumor immune microenvironment can provide effective therapeutic strategies for cancer. Neutrophils (polymorphonuclear neutrophils, PMNs) are the predominant circulating leukocyte population in humans and are vital to fight infection. Despite mounting evidence that PMNs can promote tumor progression, depleting PMNs is not a viable therapeutic option. Neutrophil extracellular traps (NETs) are networks of extracellular neutrophil DNA fibers that are capable of trapping tumor cells and promoting their growth and their metastasis. Targeting NETs can therefore be a potentially successful therapeutic option to block the tumor promoting functions of PMNs. Here we demonstrate that circulating NET levels are elevated in esophageal, gastric and lung cancer patients compared to healthy controls. This increase correlates with disease stage and NET levels are independent predictors of advanced stage. Using pre-clinical murine models of lung and colon cancer, we observe elevated NET levels in tumor bearing mice compared to non-tumor bearing mice; these levels correlated with tumor size. NET levels significantly decrease following tumor resection or treatment with DNase1, a NET degrader, or neutrophil elastase inhibitor (NEi), a NET inhibitor. NET levels do not rise following tumor inoculation in peptidyl arginine deiminase-IV knock out (PAD4-/-) mice; PAD4 being an enzyme essential for citrullination of histones, a crucial step in NET release. Moreover, PMNs from tumor bearing mice are more primed for NETosis than PMNs from non-tumor bearing mice or NEi-treated or PAD4-/- tumor bearing mice. Finally, elevated in vivo hepatic adhesion and spontaneous liver and lung metastases are observed in tumor bearing mice compared to DNase1- or NEi-treated or PAD4-/- tumor bearing mice. Therefore, inhibiting NETs represents a promising strategy to impede metastatic dissemination in several types of cancer patients. Citation Format: Roni F. Rayes, Jack G. Mouhanna, Ioana Nicolau, Phil Vourtzoumis, Carson Wong, Jules Eustache, France Bourdeau, Betty Giannias, Aya Siblini, Emma Lee, Veena Sangwan, Simon Rousseau, Daniela Quail, Logan Walsh, Nicholas Bertos, Jonathan Cools-Lartigue, Lorenzo E. Ferri, Jonathan D. Spicer. Primary tumors induce neutrophil extracellular traps with targetable metastasis promoting effects [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1508.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2019
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 79, No. 13_Supplement ( 2019-07-01), p. 2799-2799
    Abstract: With recent advances in immunotherapy, it is evident that targeting the tumor microenvironment (TME) is an effective strategy to treat lung cancer (LC), however, more than half LC patients are still resistant to therapy. Limited attention was given to the relevance of the innate immune system despite its critical role in triggering adaptive responses. Neutrophils (PMNs) are the predominant circulating leukocyte in humans. PMNs are associated with developing lesions and are the main immune component of primary non-small cell LC (NSCLC). Multiple studies support the notion that PMNs promote tumor progression, however, the exact mechanisms in which these PMNs are recruited to the primary and metastatic lung TMEs remain unclear. To this end, we examined available genomic databases of & gt; 1,000 NSCLC primary adenocarcinoma (ADC) patients and observed that high expression of all CXCR2 ligands (CXCL1-8 and MIF) correlate with poor survival in lung ADC. Lung ADC patients display one of the highest fold increases of these ligands as compared to all other cancers. We then performed shRNA knock down (KD) of CXCL1 and MIF in A549 and tested the migration of PMNs towards treated and control cell lines using the novel microfluidic device. We observe 3-fold increase of PMN migration towards A549 compared to control. This increase was significantly inhibited in MIF and CXCL1 KDs as well as using MIF and CXCL1 neutralizing antibodies (NA) as compared to controls. PMN migration was higher to A549 then to PC9EN, and treatment of PMNs with a CXCR2 NA led to a decrease in their migration to A549 while unaffecting their migration to PC9EN. Due to the lack of similar genomic databases on LC metastasis, we profiled liver homogenates of mice intrasplenically injected with liver-metastatic Lewis lung carcinoma (LLC) and observed that Cxcl1 was the most overexpressed gene as compared to non-tumor bearing mice (non-TBM). We then KD CXCL1 from the liver metastatic LLC cell line and compared its capacity to recruit PMNs in live mice using intravital microscopy. We observe a decrease in the number of PMNs around developing CXCL1 KD LLC tumors compared to control LLC. We also observe a decrease in PMN migration toward the CXCL1 KD LLC tumors as compared the control LLC. This resulted in a significant decrease in liver metastasis of the CXCL1 KD LLC as compared to control LLC injected mice. Altogether, our data highlight the importance of CXCR2-mediated PMN migration in primary LC and the establishment of liver metastasis from LC. Thus, inhibiting CXCR2 represents a promising strategy to impede primary tumor growth and metastatic dissemination of LC. Citation Format: Roni F. Rayes, Jack G. Mouhanna, Claire Wang, Simon Milette, Carson Wong, Mariana Usatii, Betty Giannias, France Bourdeau, Rachel Mot, Arvind Chandrasekaran, Christopher Moraes, Sidong Huang, Daniela Quail, Logan Walsh, Veena Sangwan, Nicholas Bertos, Pierre-Olivier Fiset, Jonathan Cools-Lartigue, Lorenzo E. Ferri, Jonathan D. Spicer. Targeting CXCR2-mediated neutrophil recruitment to lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019 ;79(13 Suppl):Abstract nr 2799.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2019
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 78, No. 13_Supplement ( 2018-07-01), p. 1099-1099
    Abstract: Neutrophils are associated with developing cancer lesions and are the main immune component of primary non-small cell lung cancer (NSCLC). Multiple studies support the notion that tumor associated neutrophils (TANs) can promote tumor progression. We hypothesize that there is a hierarchy of molecular cues produced by developing lung cancers that guide circulating neutrophils to infiltrate the tumor microenvironment and become TANs. Identifying these cues may permit modulation of neutrophil infiltration within developing lung cancers and may thereby act as an immunotherapeutic tool to suppress cancer progression and improve response to existing therapeutics. To this end, we profiled 5 established NSCLC cell lines representing the common NSCLC subtypes using a qRT-PCR 84 gene panel (A549; KRAS mutant, PC9; EGFR mutant, H1993; MET amplification, H3122; EML4-ALK translocation, HCC78; ROS1 translocation). We focused on 4 of the most commonly upregulated genes in all cell lines, which were osteopontin (Spp1), vascular endothelial growth factor A (VEGF-A), macrophage inhibitory factor (MIF), and C-X-C motif ligand 1 (CXCL1). After confirming protein expression of these targets by western blot, we performed shRNA knock down (KD) of these genes and tested the migration of neutrophils towards treated and control cell lines in a novel microfluidic device that allows increased throughput studies of neutrophil attractants. Findings from KD experiments were confirmed via antibody-mediated inhibition. We observed a 3-fold increase of neutrophil migration to the A549 cancer cell line compared to the serum free control (p=0.0265). Furthermore, this increase was inhibited in Spp1 (64% decrease), MIF (84%), VEGF (82%) KDs and their corresponding neutralizing antibodies. We have therefore identified 4 proteins that play a key role in neutrophil recruitment to NSCLC cell lines in vitro and have demonstrated the application of a simple microfluidic device to test neutrophil migration patterns. This data provides the basis for in vivo investigations to elucidate the key molecular cues for neutrophil infiltration within developing lung cancers. Citation Format: Claire Wang, Roni Rayes, Jack Mouhanna, Betty Giannias, Arvind Chandrasekaran, Rachel Mot, Christopher Moraes, Sidong Huang, Jonathan Cools-Lartigue, Nicholas Bertos, Lorenzo Ferri, Jonathan Spicer. Molecular drivers of neutrophil recruitment to primary non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1099.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2018
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: JCI Insight, American Society for Clinical Investigation, Vol. 4, No. 16 ( 2019-8-22)
    Type of Medium: Online Resource
    ISSN: 2379-3708
    Language: English
    Publisher: American Society for Clinical Investigation
    Publication Date: 2019
    detail.hit.zdb_id: 2874757-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 78, No. 13_Supplement ( 2018-07-01), p. 5176-5176
    Abstract: Gastric adenocarcinoma is the fastest rising malignancy in North America. It is commonly associated with malignant ascites (MA), the pathological accumulation of fluid containing cancer cells in the peritoneum. Peritoneal metastasis is the most common site of gastric cancer (GC) progression after curative intent surgery and is the leading cause of death. Upon peritoneal dissemination, the malignant process is deemed non-curative as it is rarely amenable to surgical resection and chemotherapeutic regimens are simply palliative. We hypothesize that cell-free MA increases the potential of GC cells to worsen peritoneal metastasis. Gastric adenocarcinoma cell lines (human: MKN-45, SNU-5, KATO III, OKAJIMA; murine NCC-S1, NCC-S1M) were incubated with cell-free MA and their metastatic ability assessed with static in vitro adhesion assays, as well as migration assays. A novel ex vivo peritoneal metastasis model further corroborated the in vitro results, where cancer cell adhesion to stripped human peritoneum was assessed by co-incubation with non- and pre-stimulated cancer cells. Gross liver metastasis was monitored over several weeks after in vivo intra-peritoneal and intra-splenic injections, whereby C57BL/6 mice were inoculated with control media or stimulated NCC-S1M cells. Incubation of human GC cells and/or human peritoneal mesothelial cells (HPMC) with cell-free MA resulted in a significant three to five-fold increase of GC cell adhesion to HPMC compared to non-stimulated condition (P & lt;0.05), as measured by inverted fluorescent microscopy. In addition, the murine GC cells incubated with MA showed a significant eight-fold increase on average (P & lt;0.05) in GC cell adhesion to HPMC compared to non-stimulated condition. Cell-free MA was shown to significantly enhance ex vivo SNU-5 cell adhesion to stripped human peritoneum by a two to four-fold increase (P & lt;0.05) compared to non-stimulated condition. Liver metastases were visible in mice that received in vivo injections of ascites-stimulated NCC-S1M cancer cells by day 25, yet not in mice inoculated with control media. Several factors (ANG-2, HGF, ICAM-1, IL-8, TIMP-2, uPAR, VEGF, NAP-2, MIF) were shown to be upregulated in MA samples compared to a cirrhotic ascites control, using a multiplex ELISA. In particular, VEGF was upregulated 11 to 25-fold, and MIF two to 12-fold. The results demonstrated that MA plays a significant role in facilitating GC cell adhesion to peritoneal mesothelia, an important early step in the peritoneal metastatic cascade. MA must therefore provide an environment that supports tumour growth and spread. A more comprehensive understanding of the molecular network is essential to determine the role of cell free MA fluid in GC progression, allowing for the identification of potential therapeutic targets for this aggressive malignancy. Citation Format: Chantelle A. Janeiro, Vivian Stavrakos, Malak Alzahrani, Roni F. Rayes, France Bourdeau, Betty Giannias, Nicholas Bertos, Veena Sangwan, Jonathan Cools-Lartigue, Jonathan D. Spicer, Lorenzo E. Ferri. Cell free malignant ascites fluid facilitates gastric adenocarcinoma peritoneal metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5176.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2018
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. 4055-4055
    Abstract: 4055 Background: Perioperative chemotherapy improves cure rate in locally advanced gastro-esophageal adenocarcinoma (GEA). Immune checkpoint inhibitors have activity in GEA. This trial is testing the hypothesis that the addition of avelumab, an anti-PD-L1 antibody, to perioperative mDCF chemotherapy, will increase the pathologic complete response (pCR) rate, a potential surrogate for overall survival, in comparison with a historical pCR rate of 7%. Methods: Single-arm phase II study (NCT03288350) of avelumab + chemotherapy (modified docetaxel/cisplatin/5-FU or mDCF) given every 2 weeks x 4 cycles before and after surgery. Planned sample size of 50 operated patients. The hypothesis cannot be refuted if ≥6 patients show pCR, the primary endpoint. Inclusion criteria: histologically proven GEA, locally advanced disease (cT3-4 and/or N+), adequate organ function, WHO performance status 0-1. Exclusion criteria: other histology, metastatic stage, use of immunosuppressants, serious autoimmune disease, intake 〉 10 mg prednisone/d. Adverse effects prospectively recorded per NCI CTCAE guidelines. Pathological response and tumor regression grade (TRG) determined by CAP criteria: 0=complete;1=near complete; 2=moderate; 3 = poor/no response. Data presented as median (range), KM determined survival. Results: Study accrual completed August 2022: 51 patients enrolled, 45 M/6 F, age 64 (18-79), ECOG 0 (35) and 1 (16). One patient withdrew consent after 2 treatment cycles and is excluded from efficacy analysis. Tumor anatomic site: Esophagus =19(38%)/gastroesophageal junction 21(42%)/subcardia stomach 10(20%). Staging: cT3 (88%), cT4 (6%), N+ (62%). Histology: all adenocarcinoma; dMMR 9/50 in 18%; CPS 〈 1, 1-5, 6-10, 〉 10 in 0%/33%/27%/40% of tumors tested. All 4 pre-operative cycles administered to 48/50 (96%); 36/50 received ≥2 adjuvant treatment cycles and 23/50 (46%) received all 8 cycles. Grade 3-4 toxicity events from neoadjuvant therapy affected: GI tract (diarrhea 4%); respiratory system (pneumonia 4%); endocrine system (adrenal insufficiency 2%). Other common side effects (grades 1-2, incidence 〉 15%) were: fatigue, diarrhea, skin rash/pruritus. Post-operative mortality at 30 and 90 days was 0/50 (0%) and 1/50 (2%). R0 resection was achieved in 48/50 (96%); a median of 36 (13-78) lymph nodes were resected. Pathological response was TRG 0/1/2/3 in 7/2/16/25 with pCR seen in 7 (14%), meeting the primary endpoint. Major pathologic response (TRG 0 and 1) was seen in 9 (18%), but without correlation with CPS or dMMR biomarker status. At 37.5 (9-71) months follow up, overall survival at 1, 2, and 3 years is 93.6%, 75.7%, and 69.2%. MPR showed a trend to improved survival ( p = 0.06). Conclusions: The neoadjuvant combination of avelumab with chemotherapy (mDCF) shows promising safety and efficacy in gastroesophageal adenocarcinoma, without obvious correlation to known biomarkers. Clinical trial information: NCT03288350 .
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Canadian Journal of Surgery, CMA Impact Inc., Vol. 66, No. 1 ( 2023-02-15), p. E79-E87
    Type of Medium: Online Resource
    ISSN: 0008-428X , 1488-2310
    Language: English
    Publisher: CMA Impact Inc.
    Publication Date: 2023
    detail.hit.zdb_id: 2026595-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...